Stage III Non-small Cell Lung Cancer
Conditions
Keywords
non-small cell lung cancer
Brief summary
In connection with the transition to the 8th version of the classification of lung cancer according to the TNM system, there are currently no precise epidemiological data on stage III NSCLC, clinical characteristics of patients in this group, approaches to therapy and treatment results in the Russian Federation. The published statistics only provide information on the overall incidence of stage III lung, trachea and bronchial cancer, which is about 40%. This observational study will make it possible to characterize the Russian population of stage III non-small cell lung cancer patients, approaches to choosing a treatment option for stage III NSCLC and the outcomes of this treatment in real clinical practice.
Interventions
None listed
Sponsors
Autonomous Non-Profit Organization National Society of Onco-Pulmonologists
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
\- stage III non-small cell lung cancer
Exclusion criteria
\- the rest of the disease stage
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Examine clinical and morphological groups | 10/01/2023 | * gender ratio (husband, wife) * smoking status (smoker, non-smoker, past smoker) * proportional distribution: squamous cell, adenocarcinoma, dimorphic cancer, others) * how many patients with mediastinal lymph node involvement: (N0, N1, N2, N3) * detection frequency: PDL (PDL \<1, PDL\> 1, PDL \<49, PDL\> 50), EGFR (EGFR + (19.24 exon) EGFR-), (ALK +, ALK -), (ROS-1 +, ROS-1 -) Get information about regional algorithms * Variants of treatment tactics: Percentage: a. Surgery v. Chemotherapy -Diagnostic algorithm: a. Morphological verification frequency b. The frequency of confirmation of metastatic lesions within the thoracic lymph nodes c. F |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Explore clinical approaches | 10/01/2023 | * Percentage of treatment options depending on: a. histological type * squamous * adenocarcinoma * dimorphic * 3 A st * 3B st |
| Diagnostic algorithm: | 10/01/2023 | v. from a variant of molecular genetic disorders * PDL \<1 * PDL\> 1 * PDL \<49 * PDL\> 50 * EGFR + |
| Percentage of treatment options | 10/01/2023 | from functional status * ECOG 1 1. only surgical treatment 2. surgical + drug treatment 3. surgical + drug treatment + radiation therapy 4. drug treatment 5. drug treatment + radiation therapy 6. radiation therapy * ECOG 2 1. only surgical treatment 2. surgical + drug treatment 3. surgical + drug treatment + radiation therapy 4. drug treatment 5. drug treatment + radiation therapy 6. radiation therapy * ECOG 3 1. only surgical treatment 2. surgical + drug treatment 3. surgical + drug treatment + radiation therapy 4. drug treatment 5. drug treatment + radiation therapy 6. radiation therapy |
Other
| Measure | Time frame | Description |
|---|---|---|
| -Evaluate the frequency of decision-making as a standard practice vs with an individual decision | 10/01/2023 | * Percentage of treatment options depending on: a. The nature of the progression * oligo progression * systemic progression b. Prior treatment options v. after surgical treatment d. Afte |
Countries
Russia
Contacts
Primary ContactKonstantin Laktionov, Professor
Backup ContactValeriy Breder, Leading Researcher
Outcome results
None listed